

August 25, 2020

**BSE Limited**

Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

Scrip code: **512529**

Symbol: **SEQUENT**

Dear Sir/Madam,

**Sub: Press Release on Board reconstitution**

We are pleased to attach a press release titled 'SeQuent announces reconstitution of Board' issued today by the Company.

We wish to take the above on record.

Thanking you,

Yours faithfully,  
For **Sequent Scientific Limited**



**Krunal Shah**  
**Company Secretary & Compliance Officer**



Encl.: As above

**SeQuent Scientific Limited**

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

## SeQuent Announces Reconstitution of Board

### Dr. Kamal K Sharma and Mr. Milind Sarwate inducted as Independent Directors

Mr. Neeraj Bharadwaj and Mr. Rahul Mukim of the Carlyle Group also joined the board

### *Mr. Gopakumar G Nair to step down as Chairman*

**Mumbai, August 25, 2020** –SeQuent Scientific Limited (Company or SeQuent) today announced reconstitution of the Board by inducting Dr. Kamal K Sharma and Mr. Milind Sarwate on the board as Independent Directors. Dr. Kamal K Sharma was also appointed as the Chairman of the Company while Mr. Milind Sarwate will head the Audit Committee.

Both the appointments are expected to add value and weightage to the Board with their strategic management skills.

The appointments come close on the heels of the recent induction of Mr. Neeraj Bharadwaj and Mr. Rahul Mukim, nominees of The Carlyle Group to the Board.

Simultaneously, as part of the reconstitution, **Dr. Gopakumar G. Nair**, Chairman stepped down from the Board.

Commenting on the development, **Mr. Manish Gupta, Managing Director of SeQuent Scientific said**, “It is indeed a privilege to have both Dr. Kamal Sharma and Mr. Milind Sarwate on the Board of SeQuent. They join SeQuent at an exciting time and their addition to the board will help us propel the Company to a new orbit in our quest to become a global animal health company from India. While Dr. Sharma with his decades of experience in the Pharmaceutical and Chemical sectors will add immense value as Chairman of the Board on the operations and the strategic sides, Mr. Sarwate with his well rounded experience will provide valuable insights in the areas of strategic finance, governance and oversight of the audit function. We look forward to their contributions and are excited they chose SeQuent.”

He also added, “ We also wish to place on record our gratitude and appreciation for Dr. Gopakumar Nair, our outgoing Chairman. Dr. Nair, who has four decades of experience in the pharmaceutical industry, led the Company in his capacity as the Chairman of the Board for over 13 years and played a pivotal role in positioning SeQuent and Alivira as a force to reckon with in the animal health space, in India and globally.”

**Dr. Kamal Sharma** is currently the non-executive Vice-Chairman of Lupin and has over 48 years of professional experience in executive positions in the Chemical and Pharmaceutical industries, and has essayed a wide variety of roles in operations, corporate development and executive management. As the Managing Director of Lupin for a decade between 2003-13, he was instrumental in Lupin achieving leadership position in key markets and businesses, transforming it into one of the largest and fastest

growing pharmaceutical companies globally. Previously, he also served as President & Chief Executive of the Life Sciences and speciality group and Member of the Management Board at RPG Enterprises. Mr. Sharma received a Bachelors Degree in Chemical Engineering from IIT Kanpur, a post graduate diploma in Industrial Management from Jamnalal Bajaj Institute of Management Studies and a Ph. D in Economics from IIT, Mumbai. He has also attended Advanced Management Program ( AMP ) at Harvard Business School, Boston

**Mr. Milind Sarwate** is the Founder & CEO of Increate Value Advisors LLP and provides advice & mentorship in value creation, effective governance and capability building, leveraging his 37-year experience including long stints in Marico & Godrej. He also invests in promising businesses/social enterprises. A Chartered Accountant, Cost Accountant, Company Secretary and a CII-Fulbright Fellow, Mr. Sarwate has eight independent directorships which include five listed companies - Mahindra Finance, Hexaware, Glenmark, Metropolis Healthcare and Matrimony.com, all with an audit committee role.

The board, as under, brings the right mix from across industries and the Company believes that the board will provide valuable perspectives as the Company continue to execute its strategy, drive profitability and enhance value for the shareholders.

- Dr. Kamal K Sharma, Chairman and Independent Director
- Dr. Kausalya Santhanam, Independent Director
- Mr. Milind Sarwate, Independent Director
- Mr. Neeraj Bharadwaj, Non-Executive Director (Nominee of the Carlyle Group)
- Mr. Rahul Mukim, Non-Executive Director (Nominee of the Carlyle Group)
- Mr. Manish Gupta, Managing Director
- Mr. Sharat Narasapur, Joint Managing Director

The Board will seek shareholders approval for the new appointees shortly.

### **About SeQuent Scientific Limited**

Sequent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India, with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. Sequent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies, including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs. Sequent is listed on the National Stock Exchange (NSE: Sequent) and BSE Limited (BSE: 512529) in India. The Carlyle Group has recently acquired control in SeQuent.

With Consolidated FY20 revenue of Rs. 11.8 billion, Net Profit of Rs. 0.8 billion and Market Capitalization of Rs. 32 billion, SeQuent is the largest animal health company from India and amongst the top 20 globally.

---

**Investor Contacts:**

<p><b>Tushar Mistry</b> Chief Financial Officer Tel: +91 22 4111 4717 <a href="mailto:tushar.m@sequent.in">tushar.m@sequent.in</a></p>	<p><b>Diwakar Pingle</b> Christensen Investor Relations Tel : +91 22 4215 0210 <a href="mailto:dpingle@christensenir.com">dpingle@christensenir.com</a></p>	<p><b>Abhishek Singhal</b> Investor Relations Consultants <a href="mailto:abhishek.s@sequent.in">abhishek.s@sequent.in</a></p>
--	---	--